There was also "no bad signal [from the data] in terms of increased rates of bleeding or infection" with the use of inclacumab, study author Dr. Jean Claude Tardif, director of the Research Center at the Montreal Heart Institute, told reporters.
One expert agreed, but said more study is needed. "This looks to be very promising, [and] I hope we get to see this continuing in larger trials," Dr. Neal Kleiman, medical director of the Cardiac Catheterization Laboratories at the Methodist DeBakey Heart and Vascular Center in Houston, said at the press briefing.
Tardif said that such a trial is being planned. The current study was funded by the drug's developer, Hoffman-La Roche Ltd.
Findings from studies that have only been presented at medical meetings, such as the Inspra trial, are typically considered preliminary until published in a peer-reviewed journal.
Find out more about drugs that work to fight heart failure at the American Heart Association.
SOURCES: March 10, 2013, press briefing, American College of Cardiology annual meeting, San Francisco, with Deepak Bhatta, M.D., chief, cardiology, Brigham and Women's Hospital, and professor, medicine, Harvard Medical School, Boston; Cindy Grines, M.D., cardiologist, Detroit Medical Center; Miguel Quinones, M.D., chair, cardiology, Methodist DeBakey Heart and Vascular Center, Houston; Jean Claude Tardif, M.D., director, Research Center at the Montreal Heart institute, and professor, medicine, University of Montreal, Canada; Neal Kleiman, medical director, Cardiac Catheterization Labo
All rights reserved